Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RemeGen CoFRA:REG +0.71%47 Cash-to-Debt is 16.51 as of Jun. 2026, which is 1401% above its 10-year median of 1.10. GuruFocus rates FRA:REG with a GF Score™ of 47/100 and a GF Value™ of €23.82 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,393 Biotechnology companies, RemeGen Co ranks better than 60.09% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. RemeGen Co's cash to debt ratio for the quarter that ended in Jun. 2026 was 16.51.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, RemeGen Cocould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for RemeGen Co's Cash-to-Debt or its related term are showing as below:
FRA:REG'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.28 Med: 1.1 Max: 17.09
Current: 16.5
During the past 6 years, RemeGen Co's highest Cash to Debt Ratio was 17.09. The lowest was 0.28. And the median was 1.10.
FRA:REG's Cash-to-Debt is ranked better than 60.09% of 1393
companies
in the Biotechnology industry
Industry Median: 7.03
vs FRA:REG: 16.50
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
RemeGen Co Cash-to-Debt Related Terms
RemeGen Co Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for RemeGen Co's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
FRA:REG vs VRTX, REGN, MRNA: Cash-to-Debt Comparison
For the Biotechnology subindustry, RemeGen Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RemeGen Co Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RemeGen Co's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where RemeGen Co's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RemeGen Co (FRA:REG) has a Cash-to-Debt of 16.51 as of Jun. 2026. This is 1401% above median its historical median of 1.10. Over the past decade, RemeGen Co's Cash-to-Debt has ranged from 0.28 to 17.09. According to the industry distribution chart, RemeGen Co ranks #556 out of 1393 companies in the Biotechnology industry, placing it in the top 39.9%.
Is RemeGen Co's Cash-to-Debt too high?
RemeGen Co's current Cash-to-Debt of 16.51 is 1401% above median its 10-year median of 1.10. Over the past 10 years, this metric has ranged from a low of 0.28 to a high of 17.09. The Biotechnology industry median Cash-to-Debt is 7.03. RemeGen Co's value of 16.51 is 134.9% above this industry median. Based on the distribution chart, RemeGen Co ranks #556 out of 1393 companies in the Biotechnology industry, which is above the industry midpoint. Overall, RemeGen Co has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does RemeGen Co's Cash-to-Debt compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RemeGen Co ranks #556 out of 1393 companies for Cash-to-Debt. This puts RemeGen Co in the upper half of its industry. The industry median Cash-to-Debt is 7.03. RemeGen Co's value of 16.51 is 134.9% above this benchmark. Historically, RemeGen Co's own Cash-to-Debt has ranged from 0.28 to 17.09 over the past decade. While the company's 10-year median is 1.10 vs. the industry median of 7.03, RemeGen Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 7.03, based on 1,393 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RemeGen Co's current Cash-to-Debt of 16.51 is 134.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 7.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RemeGen Co's current Cash-to-Debt is 16.51, which is 1401% above median its own 10-year median of 1.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RemeGen Co stock overvalued right now?
Based on GuruFocus' analysis, RemeGen Co (FRA:REG) is currently considered Possible Value Trap. The stock's GF Value™ is €23.82, compared to a current price of €8.44 — trading 64.6% below its estimated fair value. The current Cash-to-Debt is 16.51, which is 1401% above median its 10-year median of 1.10 and 134.9% above the Biotechnology industry median of 7.03. RemeGen Co's overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For RemeGen Co (FRA:REG), the current Cash-to-Debt is 16.51 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RemeGen Co (FRA:REG) Overvalued in 2026?
Based on GuruFocus' analysis, RemeGen Co stock appears to be undervalued.
The current stock price of €8.44 is trading 64.6% below its estimated GF Value™ of €23.82.
GuruFocus considers RemeGen Co to be Possible Value Trap.
Key valuation signals for FRA:REG:
Cash-to-Debt: 16.51 (1401% above median its 10-year median of 1.10)
GF Value™: €23.82 vs. price of €8.44 (64.6% below fair value)
Industry Position: 134.9% above the Biotechnology median (#556 of 1393)
No single metric tells the full story. See the FRA:REG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RemeGen Co Ltd is a Chinese biopharmaceutical company focused on the discovery, development, and commercialization of novel biologic drugs for autoimmune diseases, oncology, and ophthalmic conditions. Its lead products are telitacicept (RC18), a fusion protein targeting B-lymphocyte stimulator and a proliferation-inducing ligand approved in China for systemic lupus erythematosus, and disitamab vedotin (RC48), an antibody-drug conjugate targeting HER2 for certain cancers, developed in partnership with Seagen. The company also maintains earlier-stage pipeline candidates in immunology and oncology. RemeGen sells its approved therapies primarily in China through its own sales force and via licensing and collaboration agreements with partners for development and commercialization in other territories, including the United States and other international markets. Revenue is generated mainly from product sales in China, supplemented by licensing, milestone, and royalty payments from global partners.
47GF Score
Get the complete analysis for FRA:REG
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:REG has been successfully added to your 
